Recent Updates
Recently added Catalysts

CardiolRx

Phase 3

Recurrent Pericarditis | Small molecule | Other |Cardiol Therapeutics Inc.|Last Updated: Jun 3, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment137
FDA Designations
ORPHAN_DRUG
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06708299CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)PHASE3 RECRUITING 110Apr 7, 2025Oct 21, 2026Jun 3, 202627 United States, Canada +2
NCT05494788Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)PHASE2 COMPLETED 27Jan 9, 2023Sep 6, 2024Oct 20, 20258 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Recurrence of pericarditis
24 weeks

proportions of patients free from a new episode of recurrent pericarditis\* from the timepoint of stopping the IL-1 blocker to Week 24

11-point NRS Pain Score
8 weeks

Change in pain score from baseline using 11-point NRS after 8 weeks of treatment. Nominal Rating Scale from 0 to 10, where 0 represents no pain and 10 maximum pain.

Secondary Endpoints
Percentage of days with no or minimal pain
24 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
CardiolRxACTIVE_COMPARATOR* Initial starting dose (Day 1, evening dose to Day 3, morning dose): 5 mg/kg of body weight CardiolRx b.i.d. * Day 3, evening dose to Day 10, morning dose: 7.5 mg/kg of body weight CardiolRx b.i.d. * Day 10, evening dose to morning dose of the Week 24 Visit: 10 mg/kg of body weight CardiolRx b.i.d.
PlaceboPLACEBO_COMPARATOR* Initial starting dose (Day 1, evening dose to Day 3, morning dose): 5 mg/kg of body weight matching placebo b.i.d. * Day 3, evening dose to Day 10, morning dose: 7.5 mg/kg of body weight matching placebo b.i.d. * Day 10, evening dose to morning dose of the Week 24 Visit: 10 mg/kg of body weight matching placebo b.i.d.
Interventions
NameTypeDescription
CardiolRxDRUGThe intervention will be administered orally (via syringe) with food twice daily.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites27

Inclusion Criteria: 1. Patients 18 years of age or older 2. A history of recurrent pericarditis with stable disease and currently being treated with an IL-1 blocker, scheduled to be discontinued. Stable disease is defined as: * treatment with an IL-1 blocker for at least 12 months, * free of...

Countries:United StatesCanadaGreeceItaly
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 4, 2026NCT06708299lastUpdatePostDate: changed
LOWJun 4, 2026NCT06708299lastUpdatePostDate: changed
LOWJun 4, 2026NCT06708299lastUpdatePostDate: changed
LOWJun 4, 2026NCT06708299lastUpdatePostDate: changed
LOWJun 4, 2026NCT06708299lastUpdatePostDate: changed
LOWMay 26, 2026NCT06708299primaryCompletionDate: changed
LOWMay 24, 2026NCT06708299studyFirstPostDate: changed